The changing epidemiology of invasive candidiasis, along with concerns for the emergence of drug resistance, necessitates the identification of patients at increased risk of non-albicans Candida (NAC) to optimize selection of antifungal therapy. The major findings of a study regarding the demographic characteristics, costs, and outcomes of nonneutropenic patients with candidemia due to NAC are discussed. Given available treatment options, such risk assessment is most relevant to initial empiric therapy in stable patients without neutropenia who might be candidates for initial therapy with an azole (eg, fluconazole). The study's investigators reinforce the need for timely antifungal therapy for patients with candidemia.
PfallerMAPappasPGWingardJR. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis2006;43(suppl):S3–14.
2.
ZaoutisTEArgonJChuJBerlinJAWalshTJFeudtnerC. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis2005;41:1232–9.
3.
MorrellMFraserVJKollefMH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother2005;49:3640–5.
4.
DavisSLVazquezJAMcKinnonPS. Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in nonneutropenic patients. Ann Pharmacother2007;41:568–73. Epub 20 Mar 2007. DOI 10.1345/aph.1H516
5.
PappasPGRexJHSobelJD. Guidelines for treatment of candidiasis. Clin Infect Dis2004;38:161–89.
6.
ColomboALPerfectJDiNubileM. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Micro Infect Dis2003;22:470–4.
7.
PfallerMADiekemaDJ, International Fungal Surveillance Participant Group. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect2004;10(suppl 1):11–23.
8.
PappasPGRexJHLeeJ. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis2003;37:634–43.
9.
FluckigerUMarchettiOBilleJ. Treatment options of invasive fungal infections in adults. Swiss Medical Wkly2006;136:447–63.
10.
Ostrosky-ZeichnerLRexJHPappasPG. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother2003;47:3149–54.
LinMYCarmeliYZumstegJ. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case–control study. Antimicrob Agents Chemother2005;49:4555–60.
13.
AlmiranteBRodriguezDCuenca-EstrellaM. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case–control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol2006;44:1681–5.
14.
WeinbergerMLeiboviciLPerezS. Characteristics of candidaemia with Candida albicans compared with non-albicans Candida species and predictors of mortality. J Hosp Infect2005;61:146–54.
15.
HopeWMortonAEisenDP. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect2002;50:56–65.
